An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-3702PMID 23459720PMCID PMC3630245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term survival analysis of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA levels

  2013cited by this paper
• Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.

  2012influential reference
• Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.

  2011cited by this paper
• Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

  2009cited by this paper
• Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience.

  2006cited by this paper
• Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia

  2005cited by this paper
• A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma

  2005cited by this paper
• Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.

  2005cited by this paper
• Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.

  2004cited by this paper
• Sample size requirements for the design of reliability study: review and new results

  2004cited by this paper
• The role of measurement reliability in clinical trials

  2004cited by this paper
• Intensity‐modulated radiotherapy for early‐stage nasopharyngeal carcinoma

  2004cited by this paper
• Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.

  2004cited by this paper
• Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: Time for large‐scale clinical studies?

  2003cited by this paper
• Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

  2002cited by this paper
• Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer.

  2002cited by this paper
• p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

  2001cited by this paper
• A Possible Noninvasive Method for the Detection of Bladder Cancer in Patients

  2001cited by this paper
• Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.

  2001cited by this paper
• Gene Therapy for Cardiovascular Disorders

  2001cited by this paper
• Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.

  2000cited by this paper
• Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.

  1999cited by this paper
• Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.

  1999cited by this paper
• Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma.

  1998cited by this paper
• Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

  1998cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Highly-multiplex detection of plasma cell-free human papillomavirus-16 DNA in oropharyngeal carcinoma.

  2025cites this paper
• Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines

  2025influential citation
• Nasopharyngeal Cancer Screening: Methods, Target Populations, and Next Steps.

  2025cites this paper
• Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China

  2025cites this paper
• Liquid Biopsies in Head and Neck Cancers: Recent Developments Across Biofluids, Analytes, and Molecular Features

  2025cites this paper
• Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study.

  2025cites this paper
• Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050

  2025cites this paper
• Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma.

  2025cites this paper
• Update on Imaging of Nasopharyngeal Carcinoma.

  2025cites this paper
• Recent advances in refinement of the NPC TNM staging system

  2025cites this paper
• Application of circulating tumor DNA liquid biopsy in nasopharyngeal carcinoma: A case report and review of literature

  2025cites this paper
• ETS Translocation Variant 5 Negatively Modulates Innate Immunity to Facilitate Epstein‐Barr Virus Reactivation

  2025cites this paper
• Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review

  2025cites this paper
• Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations

  2025cites this paper
• First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies.

  2025cites this paper
• Development and Internal Validation of a Prediction Model for Nasopharyngeal Carcinoma: Using BMI and Inflammatory Response for Deciding Sequence of Chemotherapy

  2024cites this paper
• Research Progress of Traditional Drug Therapies for Nasopharyngeal Carcinoma by the PI3K/AKT Signaling Pathway

  2024cites this paper
• Identification of High-Incidence Populations in the United States for anti-Epstein Barr Virus Serologic Screening for Nasopharyngeal Carcinoma.

  2024cites this paper
• An individualized immune prognostic signature in nasopharyngeal carcinoma.

  2024cites this paper
• A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma

  2024cites this paper
• Downregulation of KLF5 by EBER1 via the ERK signaling pathway in EBV-positive nasopharyngeal carcinoma cells: implications for latent EBV infection.

  2024cites this paper
• Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma

  2024cites this paper
• Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

  2024cites this paper
• Pretreatment synthetic magnetic resonance imaging predicts disease progression in nonmetastatic nasopharyngeal carcinoma after intensity modulation radiation therapy

  2023cites this paper
• Recent Advances in Assessing the Clinical Implications of Epstein-Barr Virus Infection and Their Application to the Diagnosis and Treatment of Nasopharyngeal Carcinoma

  2023cites this paper
• Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy

  2023cites this paper
• Development of Prognostic Nomogram Based on Lipid Metabolic Markers and Lactate Dehydrogenase in Non-Metastatic Nasopharyngeal Carcinoma

  2023cites this paper
• CRISPR Cas12a-mediated amplification-free digital DNA assay improves the diagnosis and surveillance of Nasopharyngeal carcinoma.

  2023cites this paper
• A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.

  2023cites this paper
• Lessons and Opportunities for Biomarker-Driven Radiation Personalization in Head and Neck Cancer.

  2023cites this paper
• The IPTA Nashville Consensus Conference on Post‐Transplant lymphoproliferative disorders after solid organ transplantation in children: III – Consensus guidelines for Epstein‐Barr virus load and other biomarker monitoring

  2023cites this paper
• Machine learning explainability in nasopharyngeal cancer survival using LIME and SHAP

  2023cites this paper
• MRI-based deep learning model predicts distant metastasis and chemotherapy benefit in stage II nasopharyngeal carcinoma

  2023cites this paper
• Diagnosis and monitoring of virus-associated cancer using cell-free DNA.

  2023cites this paper
• Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

  2023cites this paper
• Comparison of Real-Time PCR and Digital PCR for Detection of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma.

  2023cites this paper
• A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01‐001)

  2023cites this paper
• The prognostic nutritional index represents a novel inflammation-nutrition-based prognostic factor for nasopharyngeal carcinoma

  2023cites this paper
• Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: a multicenter study in southwestern China.

  2023cites this paper
• Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regions

  2023cites this paper
• Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

  2022cites this paper
• EBV-positive large-cell and small-cell neuroendocrine carcinoma of the nasopharynx: A case report and review of the literature

  2022cites this paper
• Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area.

  2022cites this paper
• Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers

  2022cites this paper
• Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.

  2022cites this paper
• Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response

  2022cites this paper
• Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study

  2022cites this paper
• Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

  2022cites this paper
• Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics

  2022cites this paper
• Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.

  2022cites this paper
• Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma

  2022cites this paper
• Epstein-Barr Virus DNA detection by targeted sequencing in post-treatment Plasma Samples and Prognosis of Locally Advanced Nasopharyngeal Cancer: Implications for Clinical Research.

  2022cites this paper
• Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.

  2022cites this paper
• Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma.

  2022cites this paper
• Prognostic Epstein-Barr Virus (EBV) miRNA biomarkers for survival outcome in EBV-associated epithelial malignancies: Systematic review and meta-analysis

  2022cites this paper
• Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial

  2022cites this paper
• An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma

  2022influential citation
• Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?

  2022cites this paper
• Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.

  2022cites this paper
• The Use of the EBV Blood Test in Clinical Management Decision

  2021cites this paper
• The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation.

  2021cites this paper
• Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.

  2021cites this paper
• Plasma Epstein-Barr virus DNA analysis for personalised management of nasopharyngeal carcinoma—current opportunities and challenges

  2021cites this paper
• Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases

  2021cites this paper
• Prognostic value of Epstein-Barr virus biomarkers for nasopharyngeal carcinoma staging and post-treatment surveillance

  2021cites this paper
• Epstein-Barr virus-based nasopharyngeal carcinoma population screening

  2021cites this paper
• HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

  2021cites this paper
• Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus–Related Nasopharyngeal Carcinoma

  2021cites this paper
• Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature

  2021cites this paper
• Management of Suboptimal Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Re-induction Therapy or Direct to Radiotherapy?

  2021cites this paper
• Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus.

  2021cites this paper
• A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma.

  2021cites this paper
• Advances in research on microRNAs related to the invasion and metastasis of nasopharyngeal carcinoma.

  2021cites this paper
• Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy

  2021cites this paper
• Intensity-Modulated Radiation Therapy for Nasopharyngeal Cancer

  2021cites this paper
• Technical Aspects of Epstein-Barr Viral Load Assays

  2021cites this paper
• Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.

  2021cites this paper
• New developments in nasopharyngeal cancer

  2020cites this paper
• Translational Genomics of Nasopharyngeal Cancer.

  2020cites this paper
• Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma

  2020cites this paper
• Current management of stage IV nasopharyngeal carcinoma without distant metastasis.

  2020cites this paper
• Evaluation of Prognosis in Nasopharyngeal Cancer Using Machine Learning

  2020cites this paper
• Circulating Epstein‐Barr virus microRNAs BART7‐3p and BART13‐3p as novel biomarkers in nasopharyngeal carcinoma

  2020cites this paper
• The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma.

  2020cites this paper
• Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma.

  2020cites this paper
• Integrating post-radiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.

  2020cites this paper
• Lymph-node Epstein–Barr virus concentration in diagnosing cervical lymph-node metastasis in nasopharyngeal carcinoma

  2020cites this paper
• Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy

  2020influential citation
• Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens

  2020cites this paper
• Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma

  2020cites this paper
• Cost-Effectiveness of Nasopharyngeal Carcinoma Screening with Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide.

  2020cites this paper
• Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• From Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden DIETARY HABITS, COMMENSAL MICROBIOME, AND NASOPHARYNGEAL CARCINOMA

  2020cites this paper
• Diagnostic and prognostic performance of circulating levels of the Epstein-Barr virus microRNAs BART 7-3p and BART 13-3p in nasopharyngeal carcinoma

  2020cites this paper
• Spontaneous remission of residual post‐therapy plasma Epstein–Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform‐based analysis

  2019cites this paper
• The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification

  2019cites this paper
• Standard of Care for Nasopharyngeal Carcinoma (2018–2020)

  2019cites this paper
• Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)

  2019cites this paper
• Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma

  2019cites this paper
• Resistance

  2019cites this paper